Skye Biosciences Novel Cannabinoid Derivative Reduces Pain in Animal Model Results Published in Scientific Journal

San Diego, California–(Newsfile Corp. – April 3, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that in a preclinical study using one of its experimental cannabinoid-derivative molecules, cannabidiol monovalinate hemisuccinate (“CBD-Val-HS”), called SBI-200, researchers observed significantly decreased pain responses in relevant animal pain models. In contrast to cannabidiol (“CBD”), treatment of mice with SBI-200 resulted in significant analgesic effects compared to saline placebo in two different animal pain models. Interestingly, in a hot plate model, SBI-200 yielded an anti-pain effect equivalent to an analgesic…